Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Investigational immunotherapy

1020O - A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours

Date

20 Sep 2020

Session

Proffered Paper - Investigational immunotherapy

Presenters

Manish Sharma

Citation

Annals of Oncology (2020) 31 (suppl_4): S645-S671. 10.1016/annonc/annonc279

Authors

M. Sharma1, R.E. Sanborn2, G.M. Cote3, J.C. Bendell4, S. Kaul5, F. Chen6, A. Berezhnoy7, P. Moore7, E. Bonvini8, B.J. Sumrow9, J.J. Luke10

Author affiliations

  • 1 Hematology And Oncology, START Midwest, 49546 - Grand Rapids/US
  • 2 Medical Oncology, Earle A. Chiles Research Institute, Providence Cancer Institute, 97213 - Portland/US
  • 3 Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
  • 4 Medical Oncology, Sarah Cannon Research Institute, 37203 - Nashville/US
  • 5 Biostatistics, Bio-ClinPharm Consulting, LLC, 08512 - Cranbury/US
  • 6 Pathology, MacroGenics, Inc., 94005 - Brisbane/US
  • 7 Research, MacroGenics, Inc., 20850 - Rockville/US
  • 8 Clinical Development, MacroGenics, Inc., 20850 - Rockville/US
  • 9 Clinical Research & Development, MacroGenics, Inc., 20850 - Rockville/US
  • 10 Department Of Medicine, UPMC Hillman Cancer Center, 15232 - Pittsburgh/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1020O

Background

MGD019 is a bispecific, Fc-bearing (IgG4) DART molecule that blocks PD-1 and CTLA-4, with increased activity on dual PD-1/CTLA-4-expressing cells. MGD019 enhances in vitro T-cell responses to levels achieved by a combination of nivolumab and ipilimumab replicas. MGD019 was well tolerated in cynomolgus monkeys, with biological evidence of CTLA-4 antagonism but a safety profile similar to PD-1 blockade alone. MGD019 may offer risk/benefit improvements vs PD-1 plus CTLA-4 combinations.

Methods

This study characterizes safety, tolerability, dose-limiting toxicities, maximum tolerated dose (MTD), PK/PD, and preliminary antitumor activity of MGD019 in patients (pts) with advanced solid tumors. Dose Escalation enrolled pts in a 3+3+3 design up to 10 mg/kg. Cohort Expansion will further characterize safety and antitumor activity per RECIST v1.1 in pts treated at the MTD/MAD.

Results

At data-cutoff, 33 pts (39% checkpoint-experienced, 3 median prior lines of therapy) were treated in Dose Escalation from 0.03 to 10 mg/kg. No MTD was defined. Treatment-related adverse events (TRAEs) occurred in 26/33 (78.8%) pts, most commonly fatigue (24%), nausea, arthralgia, pruritus, and rash (18% each). The rate of Grade ≥ 3 TRAEs was 24.2%. Immune-related SAEs included enteritis, enterocolitis, pneumonitis, and myocarditis (n=1 each). Half-life was 12 days; full on-target binding to circulating T cells sustained through trough was observed at doses ≥ 3.0 mg every 3 weeks. Among 25 response-evaluable pts, 4 objective responses were observed (microsatellite stable colorectal cancer, metastatic thymoma [both confirmed PRs], anti-PD-L1-refractory serous fallopian tube carcinoma [unconfirmed PR with >50% reduction of CA-125], and prostatic adenocarcinoma [confirmed CR with resolution of PSA]); 9 pts had stable disease. Dose-dependent ICOS upregulation on circulating CD4+ T cells was evident, consistent with CTLA-4 engagement. Potential correlative biomarkers are being investigated.

Conclusions

MGD019 has demonstrated an acceptable safety profile and encouraging early evidence of anti-tumor activity.

Clinical trial identification

NCT03761017.

Editorial acknowledgement

Legal entity responsible for the study

MacroGenics, Inc.

Funding

MacroGenics, Inc.

Disclosure

M. Sharma: Advisory/Consultancy: AbbVie; Advisory/Consultancy: Eisai; Advisory/Consultancy, Research grant/Funding (institution): Exelixis; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Bayer; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Bolt Biotherapeutics; Research grant/Funding (institution): Compugen; Research grant/Funding (institution): Coordinaton; Research grant/Funding (institution): Effector Therapeutics; Research grant/Funding (institution): Ikena; Research grant/Funding (institution): InhibRx; Research grant/Funding (institution): Klus; Research grant/Funding (institution): MacroGenics; Research grant/Funding (institution): Symphogen; Research grant/Funding (institution): Syros; Research grant/Funding (institution): Tempest Therapeutics; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Alpine; Research grant/Funding (institution): Genmab; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Shattuck; Research grant/Funding (institution): Sapience. R.E. Sanborn: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Speaker Bureau/Expert testimony: Amgen; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Peregrine Pharmaceuticals; Advisory/Consultancy: ARIAD/Takeda; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Celldex; Advisory/Consultancy: AbbVie; Research grant/Funding (self): Merck; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): MedImmune. G.M. Cote: Advisory/Consultancy, Research grant/Funding (institution): Agios; Advisory/Consultancy, Research grant/Funding (institution): PharmaMar; Advisory/Consultancy, Research grant/Funding (institution): Epizyme; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): MacroGenics; Research grant/Funding (institution): Plexxicon; Research grant/Funding (institution): Merck KGaA; Research grant/Funding (institution): CBA; Research grant/Funding (institution): Springworks; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Boston Biomedical; Research grant/Funding (institution): Bavarian Nordic; Advisory/Consultancy, Medical Advisory Board: Chordoma Foundation; Advisory/Consultancy, Scientific Advisory Committee: Angiosarcoma AwarenessFoundation. J.C. Bendell: Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Stemcentrx; Research grant/Funding (institution): ADC Therapeutics; Research grant/Funding (institution): Agios; Research grant/Funding (institution): Arcus Biosciences; Research grant/Funding (institution): ARMO Biosciences; Research grant/Funding (institution): Array BioPharma; Research grant/Funding (institution): Arrys Therapeutics; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): BeiGene; Research grant/Funding (institution): Bellicum Pharmaceuticals; Research grant/Funding (institution): Bicycle Therapeutics; Research grant/Funding (institution): Blueprint Medicine; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Boston Biomedical; Research grant/Funding (institution): BMS; Research grant/Funding (institution): CALGB; Research grant/Funding (institution): Calithera Biosciences; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Cyteir Therapeutics; Research grant/Funding (institution): CytomX; Research grant/Funding (institution): eFFECTOR Therapeutics; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): EMD Serono; Research grant/Funding (institution): Evelo Biosciences; Research grant/Funding (institution): Genentech/Roche; Research grant/Funding (institution): Five Prime Therapeutics; Research grant/Funding (institution): Forty Seven. S. Kaul: Shareholder/Stockholder/Stock options: AbbVie; Shareholder/Stockholder/Stock options: Bristol-Myers Squibb; Shareholder/Stockholder/Stock options: Johnson & Johnson; Shareholder/Stockholder/Stock options: Merck; Shareholder/Stockholder/Stock options: CVS; Shareholder/Stockholder/Stock options: Walgreens; Shareholder/Stockholder/Stock options: Abbott; Shareholder/Stockholder/Stock options: Baxter; Shareholder/Stockholder/Stock options: Boston Scientific; Shareholder/Stockholder/Stock options: Medtronics; Shareholder/Stockholder/Stock options: United Healthcare; Advisory/Consultancy: MacroGenics; Advisory/Consultancy, Travel/Accommodation/Expenses: PharmaEssentia; Advisory/Consultancy: Bristol-Myers Squibb. F. Chen: Shareholder/Stockholder/Stock options, Full/Part-time employment: MacroGenics, Inc. A. Berezhnoy: Shareholder/Stockholder/Stock options, Full/Part-time employment: MacroGenics, Inc. P. Moore, E. Bonvini: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment: MacroGenics, Inc. B.J. Sumrow: Shareholder/Stockholder/Stock options, Full/Part-time employment: MacroGenics, Inc. J.J. Luke: Advisory/Consultancy: TTC Oncology; Advisory/Consultancy: 7 Hills; Advisory/Consultancy, Shareholder/Stockholder/Stock options: Alphamab Oncology; Advisory/Consultancy, Shareholder/Stockholder/Stock options: Pyxis; Advisory/Consultancy, Research grant/Funding (institution): Spring bank; Advisory/Consultancy: Tempest; Advisory/Consultancy, Research grant/Funding (institution): AbbVie; Advisory/Consultancy, Travel/Accommodation/Expenses: Akrevia; Advisory/Consultancy, Research grant/Funding (institution): Algios; Advisory/Consultancy, Research grant/Funding (institution): Array; Advisory/Consultancy, Research grant/Funding (institution): Astellas; Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy: Eisai; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: EMD Serono; Advisory/Consultancy: Ideava; Advisory/Consultancy, Research grant/Funding (institution): Incyte; Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck; Advisory/Consultancy, Travel/Accommodation/Expenses: Mersana; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy: PTx; Advisory/Consultancy, Travel/Accommodation/Expenses: RefleXion; Advisory/Consultancy: Regeneron; Advisory/Consultancy: Rubius; Advisory/Consultancy: Silicon; Advisory/Consultancy, Research grant/Funding (institution): Tesaro; Advisory/Consultancy: Vividion; Research grant/Funding (institution): MacroGenics; Advisory/Consultancy: Arch Oncology.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings